MX2018013584A - Formulaciones de antibioticos glicopeptidicos estabilizados. - Google Patents

Formulaciones de antibioticos glicopeptidicos estabilizados.

Info

Publication number
MX2018013584A
MX2018013584A MX2018013584A MX2018013584A MX2018013584A MX 2018013584 A MX2018013584 A MX 2018013584A MX 2018013584 A MX2018013584 A MX 2018013584A MX 2018013584 A MX2018013584 A MX 2018013584A MX 2018013584 A MX2018013584 A MX 2018013584A
Authority
MX
Mexico
Prior art keywords
glycopeptide antibiotic
antibiotic formulations
formulations
stabilized glycopeptide
stabilized
Prior art date
Application number
MX2018013584A
Other languages
English (en)
Inventor
Jasprica Ivona
KESER Sabina
Le-Cunff Jerome
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of MX2018013584A publication Critical patent/MX2018013584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En el presente documento se describen formulaciones líquidas de antibióticos glicopeptídicos o sales farmacéuticamente aceptables de estos, en donde el antibiótico glicopeptídico se selecciona de entre vancomicina, telavancina, oritavancina, teicoplanina y dalbavancina Dichas formulaciones son adecuadas como soluciones de infusión o como concentrado para hacer soluciones de infusión.
MX2018013584A 2016-05-09 2017-05-04 Formulaciones de antibioticos glicopeptidicos estabilizados. MX2018013584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333357P 2016-05-09 2016-05-09
PCT/EP2017/060653 WO2017194385A1 (en) 2016-05-09 2017-05-04 Stabilized glycopeptide antibiotic formulations

Publications (1)

Publication Number Publication Date
MX2018013584A true MX2018013584A (es) 2019-04-01

Family

ID=58745200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013584A MX2018013584A (es) 2016-05-09 2017-05-04 Formulaciones de antibioticos glicopeptidicos estabilizados.

Country Status (20)

Country Link
US (1) US10729708B2 (es)
EP (1) EP3454883A1 (es)
JP (1) JP6946343B2 (es)
KR (1) KR20190005940A (es)
CN (1) CN109069580A (es)
AR (1) AR109454A1 (es)
AU (1) AU2017262943B2 (es)
BR (1) BR112018072948A2 (es)
CA (1) CA3021935A1 (es)
CL (1) CL2018003147A1 (es)
CO (1) CO2018011701A2 (es)
EA (1) EA201892413A1 (es)
IL (1) IL262796A (es)
JO (2) JOP20170111B1 (es)
MX (1) MX2018013584A (es)
SA (1) SA518400392B1 (es)
SG (1) SG11201809908TA (es)
TW (2) TWI772296B (es)
UY (1) UY37233A (es)
WO (1) WO2017194385A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6797795B2 (ja) 2014-11-06 2020-12-09 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ グリコペプチド組成物
WO2021231361A1 (en) * 2020-05-11 2021-11-18 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing active metabolites of remdesivir for inhalation
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
WO2023211501A1 (en) * 2022-04-26 2023-11-02 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
US12070485B2 (en) 2022-10-12 2024-08-27 Xellia Pharmaceuticals Aps Liquid dalbavancin compositions
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
EP4431083A1 (en) * 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1278549A (en) * 1916-12-16 1918-09-10 J E Simmons Nut and bolt lock.
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
CA2238872A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
CA2726789A1 (en) 2000-02-05 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
US6831150B2 (en) * 2000-05-02 2004-12-14 Theravance, Inc. Reductive alkylation process
WO2001097851A2 (en) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
WO2005042584A2 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
UA91208C2 (ru) 2005-02-14 2010-07-12 Венус Ремедиз Лимитед Фармацевтическая композиция, которая содержит антибактериальный гликопептид и цефалоспорин, для терапии резистентных инфекционных состояний
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
WO2009036121A1 (en) 2007-09-12 2009-03-19 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102755629A (zh) * 2012-08-02 2012-10-31 上海瑞创医药科技有限公司 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用
CN104884047A (zh) * 2012-11-29 2015-09-02 英斯梅德股份有限公司 稳定的万古霉素制剂
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
JP6797795B2 (ja) * 2014-11-06 2020-12-09 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ グリコペプチド組成物
EP3302494A4 (en) 2016-01-08 2019-01-23 Gufic Biosciences Limited FREEZE-DRIED PARENTERAL COMPOSITION OF TIGECYCLIN AND METHOD FOR THE MANUFACTURE THEREOF
JP2019512538A (ja) * 2016-02-18 2019-05-16 メリンタ セラピューティクス、 インコーポレイテッドＭｅｌｉｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． オリタバンシン製剤

Also Published As

Publication number Publication date
TWI772296B (zh) 2022-08-01
AR109454A1 (es) 2018-12-12
BR112018072948A2 (pt) 2019-02-19
US20190175632A1 (en) 2019-06-13
AU2017262943A1 (en) 2018-11-22
CA3021935A1 (en) 2017-11-16
IL262796A (en) 2018-12-31
EA201892413A1 (ru) 2019-05-31
SA518400392B1 (ar) 2022-05-09
CN109069580A (zh) 2018-12-21
JOP20220039A1 (ar) 2023-01-30
JP6946343B2 (ja) 2021-10-06
KR20190005940A (ko) 2019-01-16
US10729708B2 (en) 2020-08-04
SG11201809908TA (en) 2018-12-28
CO2018011701A2 (es) 2019-02-08
JOP20170111B1 (ar) 2022-03-14
TW201740955A (zh) 2017-12-01
UY37233A (es) 2018-01-02
TW202133875A (zh) 2021-09-16
TWI769694B (zh) 2022-07-01
EP3454883A1 (en) 2019-03-20
CL2018003147A1 (es) 2018-12-28
JP2019518733A (ja) 2019-07-04
WO2017194385A1 (en) 2017-11-16
AU2017262943B2 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JOP20220039A1 (ar) صيغ ثابتة لمضاد حيوي من ببتيد سكري
EP3813715A4 (en) SYSTEMS AND METHODS FOR CONCOMITANT MEDICAL INTERVENTIONS
EP4282489A3 (en) Treatment of clostridium difficile infection
MX2022000056A (es) Peptidos anti-microbianos estabilizados.
EP3749190A4 (en) SYSTEM AND METHOD OF INTERFACING WITH A BIOLOGICAL FABRIC
EP3576598A4 (en) SYSTEMS AND PROCEDURES FOR REGISTRATION FOR IMAGE-GUIDED PROCEDURES
EP3576663A4 (en) IMAGE GUIDED PROCEDURE RECORDING SYSTEMS AND METHODS
EP3934519A4 (en) SURGICAL RECORDING SYSTEMS AND METHODS
AU2017278331B2 (en) Transcatheter prosthetic heart valve delivery system with lateral offset control
EP3576653A4 (en) SYSTEM AND PROCEDURE FOR DELIVERY AND POSITIONING OF SURGICAL IMPLANTS
EP3731846A4 (en) DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF INFECTIONS
EP3903745A4 (en) DELIVERY SYSTEM FOR A MEDICAL IMPLANT
WO2019032936A8 (en) LINCONSAMIDE ANTIBIOTICS AND USES THEREOF
MX2021007524A (es) Analogos de rifamicina y conjugados de farmaco-anticuerpo de los mismos.
EP3706729A4 (en) FUSOGENIC COMPOUNDS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES
EP3545916A4 (en) MEDICAL INTERVENTION INSTRUMENT DELIVERY SYSTEM
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
EP3592349A4 (en) ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS, FOR THE TREATMENT OF PSORIASIS
GB201906653D0 (en) Polypeptides for treatment of bacterial infections
EP3865140A4 (en) PREVENTATIVE AND/OR THERAPEUTIC AGENT FOR CLOSTRIDIUM DIFFICILE INFECTION
EP3863609A4 (en) SMALL POLYMERIC CARRIERS FOR DELIVERY OF ACTIVE INGREDIENTS
EP3801703A4 (en) IN-FABRIC DRUG DELIVERY SYSTEM
EP4004180A4 (en) SCALABLE BIOREACTOR SYSTEMS AND TISSUE GROWING METHODS
WO2014176068A3 (en) Treatment and prevention of bacterial skin infections using oritavancin
EP3836866A4 (en) SYSTEMS FOR THE ENTERIC DELIVERY OF THERAPEUTIC AGENTS